和黃醫藥:未有具體再上市計劃 關注香港及上海市場情況
長和(00001.HK)有份投資的和黃醫藥(HCM.US)首席財務官鄭澤鋒在全年業績網上會議表示,近期市場對公司再上市計劃有不同報道,但公司目前仍在探討上市機會,未有具體計劃,會持續關注香港及上海等其他證券市場的情況。
首席執行官賀雋補充指,過去一年多上海科創板有良好發展,香港容許未錄盈利生物科技商上市後,亦提供很多渠道及融資機會,會繼續關注不同市場,強調公司未有在港上市的具體計劃及時間表。
公司去年虧損擴大至逾1.25億美元,賀雋稱公司有很多全球性研發正在進行,預料研發開支今年會進一步增至約3億美元。不過隨著多種藥物陸續商業化,包括已於中國開始銷售的「愛優特」和「蘇泰達」,及料將於年中獲批上市的「賽沃替尼」,估計公司今年收入已可大幅增長達四倍,到1.1億至1.3億美元,有助抵銷研發支出。在未來收入料可顯著提升下,預期公司於2024年至2025年可非常接近收支平衡。
另外,鄭澤鋒提到,未來五年公司將投入1.3億美元興建位於上海的新生產廠房,建成後產能料可達現時蘇州廠房的五倍,有望滿足額外的全球生產需求。而公司手頭現金充裕,足以應付未來兩年以上的營運,公司亦會繼續評估出售非處方藥等非核心資產的機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.